Imperial College London
Portrait Picture

Dr Paul Turner

Faculty of Medicine, National Heart & Lung Institute

Reader in Paediatric Allergy & Clinical Immunology
 
 
 
//

Contact

 

+44 (0)20 3312 7754p.turner

 
 
//

Location

 

Children's Clinical Research FacilityCambridge WingSt Mary's Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Turner:2021:10.1016/j.waojou.2021.100517,
author = {Turner, PJ and Ansotegui, IJ and Campbell, DE and Cardona, V and Ebisawa, M and El-Gamal, Y and Fineman, S and Geller, M and Gonzalez-Estrada, A and Greenberger, PA and Leung, ASY and Levin, ME and Muraro, A and SÁnchez, Borges M and Senna, G and Tanno, LK and Yu-Hor, Thong B and Worm, M and WAO, Anaphylaxis Committee},
doi = {10.1016/j.waojou.2021.100517},
journal = {The World Allergy Organization Journal},
title = {COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee},
url = {http://dx.doi.org/10.1016/j.waojou.2021.100517},
volume = {14},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Vaccines against COVID-19 (and its emerging variants) are an essential global intervention to control the current pandemic situation. Vaccines often cause adverse events; however, the vast majority of adverse events following immunization (AEFI) are a consequence of the vaccine stimulating a protective immune response, and not allergic in etiology. Anaphylaxis as an AEFI is uncommon, occurring at a rate of less than 1 per million doses for most vaccines. However, within the first days of initiating mass vaccination with the Pfizer-BioNTech COVID-19 vaccine BNT162b2, there were reports of anaphylaxis from the UK and USA. More recent data implies an incidence of anaphylaxis closer to 1:125,000 doses with respect to the Pfizer-BioNTech vaccine. In this position paper, we discuss the background to reactions to the current COVID-19 vaccines and relevant steps to mitigate against the risk of anaphylaxis as an AEFI. We propose a global surveillance strategy led by allergists in order to understand the potential risk and generate data to inform evidence-based guidance, and thus provide reassurance to public health bodies and members of the public.
AU  - Turner,PJ
AU  - Ansotegui,IJ
AU  - Campbell,DE
AU  - Cardona,V
AU  - Ebisawa,M
AU  - El-Gamal,Y
AU  - Fineman,S
AU  - Geller,M
AU  - Gonzalez-Estrada,A
AU  - Greenberger,PA
AU  - Leung,ASY
AU  - Levin,ME
AU  - Muraro,A
AU  - SÁnchez,Borges M
AU  - Senna,G
AU  - Tanno,LK
AU  - Yu-Hor,Thong B
AU  - Worm,M
AU  - WAO,Anaphylaxis Committee
DO  - 10.1016/j.waojou.2021.100517
PY  - 2021///
SN  - 1939-4551
TI  - COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee
T2  - The World Allergy Organization Journal
UR  - http://dx.doi.org/10.1016/j.waojou.2021.100517
UR  - https://www.sciencedirect.com/science/article/pii/S1939455121000119?via%3Dihub
UR  - http://hdl.handle.net/10044/1/86047
VL  - 14
ER  -
Download